Clinical Trial: Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

U.S., Dec. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07284459) titled 'Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis' on Dec. 08.

Brief Summary: This is a Ph 2, randomized, double-blind, placebo-controlled global multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of PIPE-791 in subjects with a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) with or without background treatment.

Study Start Date: Dec., 2025

Study Type: INTERVENTIONAL

Condition: Idiopathic Pulmonary Fibrosis

Intervention: DRUG: PIPE-791 Dose A

Subjects will receive daily oral doses of PIPE-791

DRUG: PIPE-791 Dose B

Sub...